C. Lebbe, et al. ESMO 2025 Abstract available on ESMO website – Download the abstract – Download the Poster
Category: 2025
Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials
C. Ottensmeier, et al. ESMO 2025 Abstract available on ESMO website – Download the abstract – Download the Poster
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
ESMO Abstract
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
Title SITC
TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma
J. Foloppe, et al. Frontiers in Microbiology Septembre 2025 – Download the Article
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data – Randomization to be Completed in Phase II Part in Q4 2025
H1 financial resultats
A Pseudocowpox virus vector to generate human B cell-based vaccines
C. Thioudellet, et al. CICON 2025 – Download the Poster
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
ESMO 2025
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independant Director
Nomination E Quiles
Utilisation de l’analyseur xCELLigence RTCA eSight pour l’évaluation de la nouvelle plateforme de virus oncolytique de Transgene
B. Moreau et al.AFH 2025Download the poster herePoster presentation